Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 681 - 700 results of 101,423 for search '(( 5 mean decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.82s Refine Results
  1. 681
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 682
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 683
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 684
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 685
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 686
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 687
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 688
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 689
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 690
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 691
    Decreased ratio of GSH/GSSG in <i>Slc1a1-</i>HET mice.

    Decreased ratio of GSH/GSSG in <i>Slc1a1-</i>HET mice. by Parisa Afshari (4423141)

    Published 2017
    Save to List
    Saved in:
  12. 692
    Expression of Aβ42 decreases K<sub>v</sub>4 protein and currents in the intact brain.

    Expression of Aβ42 decreases K<sub>v</sub>4 protein and currents in the intact brain. by Yong Ping (233004)

    Published 2015
    Save to List
    Saved in:
  13. 693
    Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection.

    Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)

    Published 2018
    Save to List
    Saved in:
  14. 694
    Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G.

    Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  15. 695
    Accumulated immature APP in response to IDN5706 is degraded by Atg5-dependent autophagy.

    Accumulated immature APP in response to IDN5706 is degraded by Atg5-dependent autophagy. by Viviana A. Cavieres (500139)

    Published 2015
    Save to List
    Saved in:
  16. 696
    Supplementary Material for: Priming short children with sex steroids prior to growth hormone testing decreases the frequency of divergent results

    Supplementary Material for: Priming short children with sex steroids prior to growth hormone testing decreases the frequency of divergent results by figshare admin karger (2628495)

    Published 2025
    Save to List
    Saved in:
  17. 697
    Data_Sheet_1_Physiological synchrony in electrodermal activity predicts decreased vigilant attention induced by sleep deprivation.docx

    Data_Sheet_1_Physiological synchrony in electrodermal activity predicts decreased vigilant attention induced by sleep deprivation.docx by Ivo V. Stuldreher (11897870)

    Published 2023
    Save to List
    Saved in:
  18. 698
    Image_3_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.tif

    Image_3_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.tif by Nobuhiko Ebisutani (9764468)

    Published 2020
    “…A murine model of chronic social defeat stress (CSDS) was established by exposing a C57BL/6N intruder mouse to a CD-1 aggressor mouse for 3–5 min. …”
    Save to List
    Saved in:
  19. 699
    Image_2_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.tif

    Image_2_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.tif by Nobuhiko Ebisutani (9764468)

    Published 2020
    “…A murine model of chronic social defeat stress (CSDS) was established by exposing a C57BL/6N intruder mouse to a CD-1 aggressor mouse for 3–5 min. …”
    Save to List
    Saved in:
  20. 700
    Image_1_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.TIF

    Image_1_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.TIF by Nobuhiko Ebisutani (9764468)

    Published 2020
    “…A murine model of chronic social defeat stress (CSDS) was established by exposing a C57BL/6N intruder mouse to a CD-1 aggressor mouse for 3–5 min. …”
    Save to List
    Saved in:

Search Tools: